Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS' skin cancer drug

The US Food and Drug Administration has approved Bristol-Myers Squibb's Yervoy for the treatment of unresectable or metastatic melanoma

The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's (BMS) Yervoy (ipilimumab) for the treatment of unresectable or metastatic melanoma.

The drug is the first approved therapy in the US that demonstrates a 'significant improvement' in overall survival for patients whose skin cancer cannot be treated with surgery or has spread to other organs.

The decision date for approval had been moved back from December 25, 2010, with the FDA determining that additional time was required to complete the review of the biologics licence application.

Yervoy recently showed positive results from a phase III study that compared the drug in combination with dacarbazine chemotherapy to the chemotherapy regimen alone.

Lamberto Andreotti, CEO, BMS said: "Today's approval of Yervoy is an example of Bristol-Myers Squibb living its mission of developing and delivering innovative medicines that address the unmet needs of patients with serious diseases."

BMS has said it expects to begin shipment of Yervoy within weeks.

A post-marketing study will also be carried out comparing the safety and efficacy of the 3mg/kg dose of the drug against an investigational 10mg/kg dose.

28th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...